While the drug never became particularly popular, it briefly entered the rave and underground clubbing scene in the UK before its sale and import were banned. It falls under the category of research chemicals, sometimes called "legal highs” if uncontrolled. Because 6-APB and other substituted benzofurans have not been explicitly outlawed in some countries, they are often technically legal, contributing to its popularity.[citation needed]
6-APB can be found in freebase, hydrochloride, and succinate form. The freebase is purportedly 20% stronger than the hydrochloride salt and 65% stronger than the succinate. This means 100 mg of 6-APB HCl is equivalent to 83 mg of 6-APB freebase and 100 mg of 6-APB succinate is equivalent to 60 mg of 6-APB freebase. Different production batches may have impurities and should be treated with care.[citation needed]
Based on anecdotal reports, the dosages for 6-APB hydrochloride are the following:
Dosage
Oral
Threshold
15 mg
Light
15–60 mg
Common
60–90 mg
Strong
90–120 mg
Heavy
120 mg +
Duration
Oral
Onset
30–60 minutes (or more)
Come up
60–120 minutes
Peak
3–4 hours
Offset
2–3 hours
Total
7–10 hours
After effects
6–48 hours
The dosages for freebases or succinates have to be adjusted accordingly.
In addition to actions at the monoamine transporters, 6-APB is a potent high-efficacypartial agonist or full agonist of the serotonin5-HT2B receptor (Ki = 3.7nM; EC50Tooltip half-maximal effective concentration = 140nM; EmaxTooltip maximal efficacy = 70%).[1] It has higher affinity for this target than any other site.[7] Moreover, unlike MDMA, 6-APB shows 100-fold selectivity for the serotonin 5-HT2B receptor over the serotonin 5-HT2A and 5-HT2C receptors in terms of affinity.[7][8] It is notably both more potent and more selective as an agonist of the serotonin 5-HT2B receptor than the reference serotonin 5-HT2B receptor agonist, BW-723C86, which is commonly used for research into the serotonin 5-HT2B receptor.[citation needed] Although much more potent at the serotonin 5-HT2B receptor, 6-APB is also a partial agonist of the serotonin 5-HT2A receptor (EC50 = 5,900nM; Emax = 43%) and shows affinity for the serotonin 5-HT2C receptor (Ki = 270nM) and the serotonin 5-HT1A receptor (Ki = 1,500nM).[6] It has been reported to act as an agonist of the serotonin 5-HT2C receptor similarly to the serotonin 5-HT2A and 5-HT2B receptors.[2][9]
Besides the serotonin 5-HT2 receptors, 6-APB has been found to bind with high affinity to the α2C-adrenergic receptor (Ki = 45nM), although the significance of this action in humans is unknown.[1] 6-APB showed little other affinity at a wide selection of other sites, with some exceptions like the rodent trace amine-associated receptor 1 (TAAR1).[1][6]
The potent agonism of the serotonin 5-HT2B receptor makes it likely that 6-APB would be cardiotoxic with chronic or long-term use, as seen with other serotonin 5-HT2B receptor agonists such as the withdrawnserotonergicanorecticfenfluramine.[1][10]
Pharmacokinetics
The pharmacokinetics of 6-APB have not been studied, however, some information can be extracted from user reports. These suggest a slow onset of 40–120 minutes. The drugs peak effects last 7 hours, followed by a comedown phase of approximately 2 hours, and after effects for up to 24 hours.[11]
6-APB and its structural isomer 5-APB have been tested with a series of agents including: Marquis, Liebermann, Mecke, and Froehde reagents.[13] Exposing compounds to the reagents gives a colour change which is indicative of the compound under test.
6-APB succinate is reported to be practically insoluble in CHCl3 as well as very minimally soluble in cold water. A batch seized by the DEA contained a 2:1 ratio of succinate to 6-APB.[14]
Synthesis
Synthesis of 6-APB and its structural isomer 4-APB[14]
The synthesis by Briner et al.[8] entailed refluxing 3-bromophenol with bromoacetaldehyde diethylacetal and sodium hydride to give the diethyl acetal, which then was heated with polyphosphoric acid to give a mixture of bromobenzofuran structural isomers: 4-bromo-1-benzofuran and 6-bromo-1-benzofuran. The isomers were separated by silica gelcolumn chromatography, then converted to their respective propanone derivatives, and then reductively aminated to give 6-APB and 4-APB, both of which were converted to their HClion pairs for further examination.
In 2014, a study funded by the Canadian Institutes of Health Research noted that 6-APB "may or may not be legal in Canada depending on how one interprets the current Act"[16] and that it could be purchased for academic purposes without an exemption from Health Canada. The study also noted how, unlike the MDMA it often serves as a replacement for in countries like the US, 6-APB's benzofuran structure does not make it a direct analogue of amphetamine despite similarities in effects.
China
6-APB has been a controlled substance in China since 1 July 2024[17]
Finland
6-APB is scheduled in government decree on narcotic substances, preparations and plants and hence is illegal.[18]
In Luxembourg, 6-APB is not cited in the list of prohibited substances.[21] Therefore, it is still a legal substance.
Netherlands
6-APB, as well as multiple substances based on the phenylethamine structure, like most cathinones and amphetamines, are banned under the Opium Law since July 1st, 2025,[22] following an amendment to deal with New Psychoactive Substances (NPS) in the Netherlands. Since this is a structural ban instead of a direct one, later substances that differ slightly but use the same skeleton will also be preemptively banned.
New Zealand and Australia
Certain countries contain a "substantially similar" catch-all clause in their drug law, such as New Zealand and Australia. This includes 6-APB as it is similar in chemical structure to the class A drug MDA, meaning 6-APB may be viewed as a controlled substance analogue in these jurisdictions.[23]
It is also classified as a narcotic substance since 2020.[25]
United Kingdom
On June 10, 2013 6-APB and a number of analogues were classified as Temporary Class Drugs in the UK following an ACMD recommendation.[10] This means that sale and import of the named substances are criminal offences and are treated as for class B drugs.[26] On November 28, 2013 the ACMD recommended that 6-APB and related benzofurans should become Class B, Schedule 1 substances.[10] On March 5, 2014 the UK Home Office announced that 6-APB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.[27]
United States
6-APB is not scheduled at the federal level in the United States,[28][failed verification] but it may be considered an analog of amphetamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.[29]
^Canal CE (2018). "Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action". New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. Cham: Springer International Publishing. pp. 227–260. doi:10.1007/164_2018_107. ISBN978-3-030-10560-0. PMC6136989. PMID29532180. Despite micromolar 5-HT1A affinities (Rickli et al. 2015b), Nbenzylphenethylamines retain potent psychedelic effects. Also, benzofurans, such as 5-APB and 6-APB, are potent and efficacious 5-HT2B agonists but have very low potency at 5-HT2A receptors. They also stimulate efflux of DA and 5-HT and have activity at TAAR1 receptors (Iversen et al. 2013; Rickli et al. 2015a), but anecdotal reports note that psychedelic effects are relatively minor compared to classic psychedelics. These observations provide further credence that the 5-HT2A receptor, but not 5-HT1A, 5-HT2B, TAAR1, or monoamine transporters, initiates psychedelic effects.
^Shaun L. Greene (2013). Novel Psychoactive Substances: Classification, Pharmacology and Toxicology Chapter 16 – Benzofurans and Benzodifurans. Boston: Academic Press. pp. 383–392. doi:10.1016/B978-0-12-415816-0.00016-X. ISBN978-0-12-415816-0.
^Nugteren-van Lonkhuyzen JJ, van Riel AJ, Brunt TM, Hondebrink L (December 2015). "Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans". Drug and Alcohol Dependence. 157: 18–27. doi:10.1016/j.drugalcdep.2015.10.011. PMID26530501.
Notes: (1) TAAR1 activity of ligands varies significantly between species. Some agents that are TAAR1 ligands in some species are not in other species. This navbox includes all TAAR1 ligands regardless of species. (2) See the individual pages for references, as well as the List of trace amines, TAAR, and TAAR1 pages. See also:Receptor/signaling modulators